Navigation Links
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:5/31/2008

tara trial to the next stage," said Dr. Kevin Judy, associate professor neurosurgery at the University of Pennsylvania School of Medicine and a principal investigator of the Cotara dosimetry trial. "Cotara's good safety profile to date is especially encouraging in view of the toxicity of the treatment options currently available to GBM patients. We look forward to further assessing its safety and anti-tumor activity at the higher doses we plan to use in the next stages of the trial."

The open label dose confirmation and dosimetry study at U.S. brain cancer centers is enrolling GBM patients with recurrent disease. Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose.

"These positive data validate a key principle underlying the Cotara program, confirming its ability to specifically concentrate in and deliver a high radiation dose to brain tumors," said Steven W. King, president and CEO of Peregrine. "These results also further confirm the key targeting attribute of Cotara, showing it results in minimal radiation exposure to other organs, including the thyroid. We also are encouraged that patients in this initial, low-dose cohort have already lived longer than the expected median survival time for GBM patients at first relapse, and we look forward to reporting further data on Cotara in the coming months."

The dosimetry study's main objectives are to confirm the maximum tolerated dose of Cotara, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In addition to the University of Pennsylvania Medical Center, the Medical University of South Carolina in Charleston and the Barrow Neurological Institute in Phoenix, Arizona are participating in the trial. A fourth study site was recently initiated at Case Western Reserve University in Cleveland, Ohio. Peregrine is also conducti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
5. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
6. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
10. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2012  InterMune, Inc. (NADSAQ: ITMN) today reported ... announced its decision granting the additional benefit ... treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  ... 4 (not quantifiable benefit)  in the rating ...
... March 15, 2012 Reportlinker.com announces that ... in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market research report ... actual market situation, trends and future outlook ...
Cached Medicine Technology:Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 2Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 3Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 4Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 5Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 6Vaccines - Asia 2
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Jan. 6 Karen Ignagni, President and CEO of America,s ... by CMS today showing that health spending in the United ... 6.1 percent in 2007. According to the CMS report, ... same rate as in 2006, but much lower than the ...
... 2009) MAQUET Inc., a subsidiary of the ... and largest surgical equipment companies in the world, ... first installation of its advanced, prefabricated VARIOP ... now enables hospitals and surgical centers to reconfigure ...
... San Francisco has received a $7.5 million grant from ... shortage of healthcare workers in Tanzania. The two-year grant ... Sciences and the Muhimbili University of Health Allied Sciences ... to enable MUHAS and other African institutions to meet ...
... veterans struggling financially due to a job loss or decreased ... of programs that can relieve the costs of health care ... in the economy, VA recognizes that many veterans will feel ... Peake. "Therefore, it is important that eligible veterans learn of ...
... Cutting calories can cut down on pounds in middle age, ... less, weigh less. , While it may sound painfully obvious, ... to long-term weight loss, because the practice can sometimes boomerang, ... suggests that eating less can pay big dividends, particularly as ...
... A survey recently conducted by the Society of ... Compliance Association (HCCA) reveals that the declining economy may ... in business. In addition, this increased risk is ... risks are expected to at best hold steady, if ...
Cached Medicine News:Health News:AHIP Statement on National Health Expenditure Data 2Health News:MAQUET opens North America's first VARIOP prefabricated operating suite system 2Health News:UCSF-Tanzania get $7.5M from Gates Foundation for partnership to train African health workers 2Health News:It Pays to Eat Less as You Age 2Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 2Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 3